BSG 2024 IBD guidelines protocol (standard operating procedures)

Abstract

IntroductionIn the past 5 years, there have been several advances in the management of inflammatory bowel disease (IBD). We aim for a new guideline to update the most recent guideline published in 2019. We present the prospective operating procedure and technical summary protocol in the manuscript.Methods‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) will be followed in the development of the guideline, approach as laid out in the GRADE handbook, supported by the WHO. The guideline development group is formed by a variety of disciplines, across both primary and secondary care that took part in an online Delphi process and split into key areas. A final consensus list of thematic questions within a ‘patient, intervention, comparison, outcome’ format has been produced and agreed in the final phase of the Delphi process.There will be a detailed technical evidence review with source data including systematic reviews appraised with AMSATAR 2 tool (Assessment of multiple systematic reviews), randomised controlled trial data that will be judged for risk of bias with the Cochrane tool and observational studies for safety concerns assessed through the Robins-I tool. Based on the available evidence, some of the recommendations will be based on GRADE while others will be best practice statements.A full Delphi process will be used to make recommendations using online response systems.This set of procedures has been approved by the Clinical Services and Standards Committee, the British Society of Gastroenterology executive board and aligned with IBD UK standards.

Quality of reporting inflammatory bowel disease randomised controlled trials: a systematic review

“…Additionally, while cautious interpretation of unclear RoB data by readers is essential, the implementation of the GRADE approach, which prioritises overall outcomes over individual study evaluations, typically leads to more guarded recommendations in evidence-based guidelines 5. This consideration gains further importance in light of the increasing integration of the GRADE methodology on an international scale, particularly in the UK, as evidenced by the forthcoming British Society of Gastroenterology guidelines 19…”

“… 5 This consideration gains further importance in light of the increasing integration of the GRADE methodology on an international scale, particularly in the UK, as evidenced by the forthcoming British Society of Gastroenterology guidelines. 19 …”

Prepublication abstract-only reports compared with full-text manuscripts for randomised controlled trials in inflammatory bowel disease: a systematic review

“…This is also key for guideline development and prescribing decision-making and given the risk of publication bias involved with excluding such works, the null position is very often to consider them. 4 They are also used often by clinicians who want to stay updated with new findings in their field and prescribing decisions, and the press for the communication of these findings to the public. It has been demonstrated in other medical fields that abstract-only reports have both methodological and outcome data reporting flaws compared with full-text manuscripts.…”

“…However, abstract-only reports are routinely used in evidence synthesis, during the period full-text manuscripts are not available, or when they do not exist. This is also key for guideline development and prescribing decision-making and given the risk of publication bias involved with excluding such works, the null position is very often to consider them 4. They are also used often by clinicians who want to stay updated with new findings in their field and prescribing decisions, and the press for the communication of these findings to the public.…”

Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge

“…As the SC administration form of these drugs was only recently introduced, most guidelines do not yet reference it. However, according to the 2024 guideline from the British Society of Gastroenterology (BSG), both administration forms are considered therapeutic options for ulcerative colitis (UC) and Crohn’s disease [ 3 ].…”